![1]()
News
Microbiome therapeutic offers durable protection against C. difficile recurrence
May 28, 2021
“The hope would be that one or more ... would probably replace the vast majority of FMT [procedures] that we do clinically,”said Dr. Sahil Khanna.
![1]()
News
New AHA/ASA guideline on secondary stroke prevention
May 27, 2021
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.
![1]()
News
Making sense of LAMA discharges
May 26, 2021
There is no evidence that insurance companies will not pay for LAMA discharges.
News
Large vessel stroke linked to AstraZeneca COVID vaccine
May 26, 2021
Three cases occurred in two women and one man in their 30s or 40s and involved blockages of the carotid and middle cerebral artery.
![1]()
News
The COVID-19 pandemic and changes in pediatric respiratory and nonrespiratory illnesses
May 26, 2021
Reduced transmission of infectious agents may not fully explain these findings.
![1]()
News
Hospital at Home: Delivering hospital-level care without the hospital
May 25, 2021
The future of HaH depends on development of a common payment model that will be adopted beyond the pandemic.
News
AHA reassures myocarditis rare after COVID vaccination, benefits overwhelm risks
May 24, 2021
As CDC investigates rare, mostly mild cases of myocarditis in adolescents and young adults given the Pfizer or Moderna vaccine, AHA emphasizes their effectiveness and strong safety record.
![1]()
News
GALACTIC-HF: Novel drug most effective in sickest HFrEF patients
May 24, 2021
In GALACTIC-HF trial, the greatest relative benefit of omecamtiv mecarbil was in the sickest HFrEF patients.
![1]()
Opinion
Cultivating emotional awareness
May 24, 2021
Cultivating emotional awareness is a simple technique to maintain equanimity as we do emotionally turbulent work.
![1]()
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
May 24, 2021
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.
